The global dry eye syndrome market size was estimated to be USD 7.69 billion in 2023 and is expected to reach at USD 18.9 billion by 2033 with a CAGR of 8.54% during the forecast period 2023-2033. Rising prevalence of dry eye syndrome, increasing prevalence of mask associated dry eye, growing demand for effective treatments, surge in awareness regarding the condition among the population, rising geriatric population as eyes produce fewer tears in the elderly leading to increased evaporation & dryness, growing usage of contact lenses serves as a development of dryness, increasing adoption of products for maintaining the health of the eyes, and surge in research & development activities for treating the condition are some of the key factors boosting the market growth.
Surge in research & development activities for treating the condition is predicted to boost the market growth during the forecast period. For instance, in September 2022, TearSolution announced encouraging outcomes from its initial human trial of Lacripep, showcasing its potential as a treatment for dry eye disease.
By Type, Evaporative dry eye syndrome was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to increasing prevalence of the disease, rise in screen time, reduced rate of blinking, & reduced tear formation due to age, growing geriatric population, and increasing product approvals. For instance, in May 2023, Bausch + Lomb Corporation and Novaliq GmbH have disclosed that the U.S. Food and Drug Administration (FDA) granted approval for MIEBO™ (perfluorohexyloctane ophthalmic solution; previously known as NOV03), to address the signs and symptoms of dry eye disease (DED). MIEBO is the sole FDA-approved treatment specifically targeting tear evaporation for DED. Additionally, Aqueous dry eye syndrome is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of the disease due to the inability of the lacrimal glands to produce tears and surge in research & development activities for the development of innovative medications.
By Product, Cyclosporine was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to rising incidences of dry eye syndrome, increasing research & development activities, and growing focus on the development of novel treatments. For instance, in August 2022, CyclASol (cyclosporine ophthalmic solution) has been submitted as a New Drug Application (NDA) to the U.S. FDA by Novaliq GmbH. CyclASol is a topical ophthalmic drug solution with anti-inflammatory and immunomodulating properties, designed for the treatment of dry eye disease. Additionally, Topical corticosteroids is predicted to grow at fastest CAGR during the forecast period owing to the quick action of corticosteroid drugs and surge in product approvals by regulatory bodies.
By Drug, Restasis was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to its rising usage in chronic dry eye symptoms and rising product approvals by regulatory bodies. For instance, in February 2022, The first generic version of Restasis (cyclosporine ophthalmic emulsion) has been approved by the US Food and Drug Administration (FDA). Mylan Pharmaceuticals Inc sponsors this newly approved generic, available as 0.05% single-use vials in the form of eye drops. Additionally, Xiidra is predicted to grow at fastest CAGR during the forecast period owing to the increasing drug approvals by the U.S. FDA for the treatment of signs & symptoms of dry eye disease.
By Dosage, Eye drops was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to the simplicity of use & administration which increases patient adherence to the therapy and rising launch of new products. For instance, in April 2021, Alcon has introduced the latest addition to its range of dry eye products in the United States - Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Drops. Additionally, Eye solutions is predicted to grow at fastest CAGR during the forecast period owing to their long-lasting effects and increasing collaborations within market players for the development of novel product.
By Distribution Channel, Retail pharmacies was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to the simple access to retail pharmacies, the availability of pharmacists to help with dosing, customer services, & consultations in some areas and increasing launch of new treatments within market through retail pharmacies. For instance, in January 2021, Eysuvis, a short-term therapy for dry eye, is now available at retail pharmacies, according to Kala Pharmaceuticals, Inc. Additionally, Online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to growing number of people buying products due to convenience, rising adoption of online pharmacies, the availability of better price in these online shops stimulates recurring buying.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing healthcare expenditure, rising adoption of advanced treatment, growing development of novel medications, and surge in product approvals by regulatory bodies. For instance, in January 2021, Eysuvis (loteprednol etabonate ophthalmic suspension, from Kala Pharmaceuticals, Inc) 0.25% has received approval from the FDA for the short-term treatment of the signs and symptoms associated with dry eye disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising healthcare infrastructure, surge in prevalence of dry eye disease, the presence of major market players, and increasing introduction of innovative treatments by leading market players. For instance, in April 2023, Sun Pharmaceutical Industries Limited revealed that one of its wholly-owned subsidiaries has introduced a new ophthalmology treatment named CEQUA in India. CEQUA is designed for patients experiencing Dry Eye Disease (DED) with inflammation, a prevalent condition. It is the first dry eye treatment in India that utilizes nanomicellar (NCELL®) technology for delivery.
Surge in research & development activities for treating the condition is predicted to boost the market growth during the forecast period. For instance, in September 2022, TearSolution announced encouraging outcomes from its initial human trial of Lacripep, showcasing its potential as a treatment for dry eye disease.
By Type, Evaporative dry eye syndrome was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to increasing prevalence of the disease, rise in screen time, reduced rate of blinking, & reduced tear formation due to age, growing geriatric population, and increasing product approvals. For instance, in May 2023, Bausch + Lomb Corporation and Novaliq GmbH have disclosed that the U.S. Food and Drug Administration (FDA) granted approval for MIEBO™ (perfluorohexyloctane ophthalmic solution; previously known as NOV03), to address the signs and symptoms of dry eye disease (DED). MIEBO is the sole FDA-approved treatment specifically targeting tear evaporation for DED. Additionally, Aqueous dry eye syndrome is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of the disease due to the inability of the lacrimal glands to produce tears and surge in research & development activities for the development of innovative medications.
By Product, Cyclosporine was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to rising incidences of dry eye syndrome, increasing research & development activities, and growing focus on the development of novel treatments. For instance, in August 2022, CyclASol (cyclosporine ophthalmic solution) has been submitted as a New Drug Application (NDA) to the U.S. FDA by Novaliq GmbH. CyclASol is a topical ophthalmic drug solution with anti-inflammatory and immunomodulating properties, designed for the treatment of dry eye disease. Additionally, Topical corticosteroids is predicted to grow at fastest CAGR during the forecast period owing to the quick action of corticosteroid drugs and surge in product approvals by regulatory bodies.
By Drug, Restasis was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to its rising usage in chronic dry eye symptoms and rising product approvals by regulatory bodies. For instance, in February 2022, The first generic version of Restasis (cyclosporine ophthalmic emulsion) has been approved by the US Food and Drug Administration (FDA). Mylan Pharmaceuticals Inc sponsors this newly approved generic, available as 0.05% single-use vials in the form of eye drops. Additionally, Xiidra is predicted to grow at fastest CAGR during the forecast period owing to the increasing drug approvals by the U.S. FDA for the treatment of signs & symptoms of dry eye disease.
By Dosage, Eye drops was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to the simplicity of use & administration which increases patient adherence to the therapy and rising launch of new products. For instance, in April 2021, Alcon has introduced the latest addition to its range of dry eye products in the United States - Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Drops. Additionally, Eye solutions is predicted to grow at fastest CAGR during the forecast period owing to their long-lasting effects and increasing collaborations within market players for the development of novel product.
By Distribution Channel, Retail pharmacies was the highest revenue-grossing segment in the global dry eye syndrome market in 2022 owing to the simple access to retail pharmacies, the availability of pharmacists to help with dosing, customer services, & consultations in some areas and increasing launch of new treatments within market through retail pharmacies. For instance, in January 2021, Eysuvis, a short-term therapy for dry eye, is now available at retail pharmacies, according to Kala Pharmaceuticals, Inc. Additionally, Online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to growing number of people buying products due to convenience, rising adoption of online pharmacies, the availability of better price in these online shops stimulates recurring buying.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing healthcare expenditure, rising adoption of advanced treatment, growing development of novel medications, and surge in product approvals by regulatory bodies. For instance, in January 2021, Eysuvis (loteprednol etabonate ophthalmic suspension, from Kala Pharmaceuticals, Inc) 0.25% has received approval from the FDA for the short-term treatment of the signs and symptoms associated with dry eye disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising healthcare infrastructure, surge in prevalence of dry eye disease, the presence of major market players, and increasing introduction of innovative treatments by leading market players. For instance, in April 2023, Sun Pharmaceutical Industries Limited revealed that one of its wholly-owned subsidiaries has introduced a new ophthalmology treatment named CEQUA in India. CEQUA is designed for patients experiencing Dry Eye Disease (DED) with inflammation, a prevalent condition. It is the first dry eye treatment in India that utilizes nanomicellar (NCELL®) technology for delivery.
Segmentation: Dry Eye Syndrome Market Report 2022 - 2033
Dry Eye Syndrome Market Analysis & Forecast by Type 2022 - 2033 (Revenue USD Bn)
- Aqueous Deficient Dry Eye Syndrome
- Evaporative Dry Eye Syndrome
Dry Eye Syndrome Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
- Artificial Tears
- Cyclosporine
- Oral Omega Supplements
- Topical Corticosteroids
Punctal Plugs
- Removable
- Dissolvable
- Others
Dry Eye Syndrome Market Analysis & Forecast by Drug 2022 - 2033 (Revenue USD Bn)
- Cequa
- Xiidra
- Eysuvis
- Restasis
- Tyrvaya
- Others
Dry Eye Syndrome Market Analysis & Forecast by Dosage 2022 - 2033 (Revenue USD Bn)
- Eye Drops
- Gels
- Eye Solutions
- Ointments
- Capsules & Tablets
Dry Eye Syndrome Market Analysis & Forecast by Distribution Channel 2022 - 2033 (Revenue USD Bn)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Dry Eye Syndrome Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Dry Eye Syndrome Market: Type Estimates & Trend Analysis
8. Dry Eye Syndrome Market: Product Estimates & Trend Analysis
9. Dry Eye Syndrome Market: Drug Estimates & Trend Analysis
10. Dry Eye Syndrome Market: Dosage Estimates & Trend Analysis
11. Dry Eye Syndrome Market: Distribution Channel Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Dry Eye Syndrome Market
14. Europe Global Dry Eye Syndrome Market
15. Asia Pacific Global Dry Eye Syndrome Market
16. Latin America Global Dry Eye Syndrome Market
17. MEA Global Dry Eye Syndrome Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Sun Pharmaceutical Industries Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Novartis AG
- AFT Pharmaceuticals
- Bausch & Lomb
- AbbVie Inc.
- Johnson & Johnson Services Inc.
- Oyster Point Pharma Inc.
- OASIS Medical
- Santen Pharmaceutical Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 7.69 Billion |
| Forecasted Market Value ( USD | $ 18.9 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
